485 related articles for article (PubMed ID: 33746966)
1. Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation.
Salem D; Chelvanambi M; Storkus WJ; Fecek RJ
Front Immunol; 2021; 12():629519. PubMed ID: 33746966
[TBL] [Abstract][Full Text] [Related]
2. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
[TBL] [Abstract][Full Text] [Related]
3. A Standardized Analysis of Tertiary Lymphoid Structures in Human Melanoma: Disease Progression- and Tumor Site-Associated Changes With Germinal Center Alteration.
Werner F; Wagner C; Simon M; Glatz K; Mertz KD; Läubli H; Griss J; Wagner SN
Front Immunol; 2021; 12():675146. PubMed ID: 34248957
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma.
Lynch KT; Young SJ; Meneveau MO; Wages NA; Engelhard VH; Slingluff CL; Mauldin IS
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103353
[TBL] [Abstract][Full Text] [Related]
5. Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure.
Lin Z; Huang L; Li S; Gu J; Cui X; Zhou Y
Sci Rep; 2020 Dec; 10(1):21530. PubMed ID: 33299035
[TBL] [Abstract][Full Text] [Related]
6. STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development.
Filderman JN; Appleman M; Chelvanambi M; Taylor JL; Storkus WJ
Front Immunol; 2021; 12():690105. PubMed ID: 34054879
[TBL] [Abstract][Full Text] [Related]
7. Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma.
Maibach F; Sadozai H; Seyed Jafari SM; Hunger RE; Schenk M
Front Immunol; 2020; 11():2105. PubMed ID: 33013886
[TBL] [Abstract][Full Text] [Related]
8. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
9. Targeting Tertiary Lymphoid Structures for Tumor Immunotherapy.
Tang H; Qiu X; Timmerman C; Fu YX
Methods Mol Biol; 2018; 1845():275-286. PubMed ID: 30141019
[TBL] [Abstract][Full Text] [Related]
10. Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.
Liu X; Tsang JYS; Hlaing T; Hu J; Ni YB; Chan SK; Cheung SY; Tse GM
Oncologist; 2017 Nov; 22(11):1316-1324. PubMed ID: 28701569
[TBL] [Abstract][Full Text] [Related]
11. A 12-chemokine gene signature is associated with the enhanced immunogram scores and is relevant for precision immunotherapy.
Li X; Wan Z; Liu X; Ou K; Yang L
Med Oncol; 2022 Jan; 39(4):43. PubMed ID: 35092511
[TBL] [Abstract][Full Text] [Related]
12. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
[TBL] [Abstract][Full Text] [Related]
13. Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma.
Rodriguez AB; Peske JD; Engelhard VH
Methods Mol Biol; 2018; 1845():241-257. PubMed ID: 30141017
[TBL] [Abstract][Full Text] [Related]
14. Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer.
An Y; Sun JX; Xu MY; Xu JZ; Ma SY; Liu CQ; Liu Z; Wang SG; Xia QD
Front Immunol; 2022; 13():1049884. PubMed ID: 36420257
[TBL] [Abstract][Full Text] [Related]
15. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma.
Siliņa K; Soltermann A; Attar FM; Casanova R; Uckeley ZM; Thut H; Wandres M; Isajevs S; Cheng P; Curioni-Fontecedro A; Foukas P; Levesque MP; Moch H; Linē A; van den Broek M
Cancer Res; 2018 Mar; 78(5):1308-1320. PubMed ID: 29279354
[TBL] [Abstract][Full Text] [Related]
16. Tertiary lymphoid structures in the era of cancer immunotherapy.
Sautès-Fridman C; Petitprez F; Calderaro J; Fridman WH
Nat Rev Cancer; 2019 Jun; 19(6):307-325. PubMed ID: 31092904
[TBL] [Abstract][Full Text] [Related]
17. Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas.
Edmonds NL; Gradecki SE; Katyal P; Lynch KT; Stowman AM; Gru AA; Engelhard VH; Slingluff CL; Mauldin IS
Oncoimmunology; 2023; 12(1):2164476. PubMed ID: 36632563
[TBL] [Abstract][Full Text] [Related]
18. Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
Cabrita R; Lauss M; Sanna A; Donia M; Skaarup Larsen M; Mitra S; Johansson I; Phung B; Harbst K; Vallon-Christersson J; van Schoiack A; Lövgren K; Warren S; Jirström K; Olsson H; Pietras K; Ingvar C; Isaksson K; Schadendorf D; Schmidt H; Bastholt L; Carneiro A; Wargo JA; Svane IM; Jönsson G
Nature; 2020 Jan; 577(7791):561-565. PubMed ID: 31942071
[TBL] [Abstract][Full Text] [Related]
19. Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies.
Trüb M; Zippelius A
Front Immunol; 2021; 12():674565. PubMed ID: 34054861
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation.
Domblides C; Rochefort J; Riffard C; Panouillot M; Lescaille G; Teillaud JL; Mateo V; Dieu-Nosjean MC
Front Immunol; 2021; 12():698604. PubMed ID: 34276690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
